Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05546749 · ClinicalTrials.gov registry record · NA

Virtual Reality for Chronic Pain and Opioid Use Disorder Pilot

A NA study of Chronic Pain and Opioid Use Disorder, sponsored by Albert Einstein College of Medicine.

Completed
Registry status
NA
Development phase
18
Enrollment target
1
Study location

NCT05546749 is a NA study of Chronic Pain and Opioid Use Disorder that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 18 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05546749, a NA study of Chronic Pain and Opioid Use Disorder, has completed, sponsored by Albert Einstein College of Medicine.

COMPLETED
Registry status
NA
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

This is a pilot feasibility study of a virtual reality device for patients with co-morbid chronic pain and opioid use disorder.

Interventions

  • DEVICE RelieVRx
  • DEVICE Sham VR

Study Locations (1)

New York

  • Melrose Clinic - The Bronx

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2023-02-08
Est. Completion 2023-07-12
Phase NA

Sponsor

Albert Einstein College of Medicine

175 total trials

What the Registry Record Tells You About NCT05546749

The ClinicalTrials.gov registry entry for NCT05546749 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (98% lower). The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Chronic Pain appearing as the primary indexed condition, and to 2 interventions - of which RelieVRx is the first listed.

NCT05546749 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05546749 about?

NCT05546749 is a clinical study titled "Virtual Reality for Chronic Pain and Opioid Use Disorder Pilot". This is a pilot feasibility study of a virtual reality device for patients with co-morbid chronic pain and opioid use disorder.

What is the current status of trial NCT05546749?

This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2023-02-08. Estimated completion is 2023-07-12.

What conditions does trial NCT05546749 study?

This clinical trial studies the following conditions: Chronic Pain, Opioid Use Disorder.

What interventions are being tested in trial NCT05546749?

The interventions under investigation include: RelieVRx (DEVICE), Sham VR (DEVICE).

Who is sponsoring clinical trial NCT05546749?

This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05546749 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.